Introduction Dysregulation of serine/threonine-specific protein kinase signaling, especially the mammalian target of rapamycin (mTOR), results in several types of tumors. mTOR regulates cellular metabolism, growth, and proliferation by signaling through mTORC1 and mTORC2 protein complexes. Everolimus belongs to a class of drugs that inhibit mTOR and provide therapeutic benefits in the management of metastatic renal cell carcinoma (RCC). This “ Journal Watch ” summarizes the trial “ Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma ,” published in BioMed Central Journal, 2018 .
Authors: Lin Yang, Anna Alyasova, Dingwei Ye, et al. What was the need for this study? The first-line agents like sorafenib and sunitinib for managing RCC are associated with a higher incidence of nausea, diarrhea, hypertension, hand-foot syndrome, and mucositis, calling for second-line…
